Regulating Compounding in the GLP-1 Era: A Conversation | Essential: The Pharmacy Compounding Podcast
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those? Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day. Links from the podcast: The latest FDA statement on DTE: https://fllw.me/4sL6zXw The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C National Association of Boards of Pharmacy: https://nabp.pharmacy Join APC! https://a4pc.org/join